• Accountable for devising and implementing creative deal structures with biotech partners • Accountable for leading negotiations for amendments to CEEDD portfolio of existing strategic alliances

• Lead Counsel for several of GlaxoSmithKline’s most prolific deal-making R&D units and Therapy Areas• Leadership Team Member for CEEDD and for Immuno-Inflammation Therapy Area Unit• Negotiation and completion of more than 50 major collaboration and licensing deals across a broad range of biotech partners as well as academic and government entity partners• Several collaborations and licensing deals resulted in products that were commercially launched or are in the late-stage GSK pipeline , e.g. Benlysta® (belimumab) and Tanzeum™ (albiglutide)• Led drafting and negotiation of strategic partnerships that included GSK’s major R&D alliances such as Human Genome Sciences, Inc., ChemoCentryx, Inc., Prosensa Therapeutics, OncoMed Pharmaceuticals, Inc, Regulus, Inc. Dynavax, Inc., and Cellzome, Inc., among others. • Lead Counsel on cutting-edge special projects such as the formation by GSK of the Cambridge-based NewCo. Tempero Pharmaceuticals, Inc., and GSK’s groundbreaking three-way gene therapy deal with the Telethon Institute of Gene Therapy (TIGET) and the Hospital San Raffaele of Milan, Italy.

Scientific Liaison Associate- External Scientific Affairs• led negotiations for numerous Material Transfer Agreements, Sponsored Research Agreements and Patent License Agreements for several therapeutic areas of Merck Research LabsResearch Biochemist• Developed key analytical assays and cGMP biopharmaceutical process purification steps and transferred steps successfully to manufacturing for several of Merck’s recombinant protein and vaccine products such as Vaqta® (HepA) and Gardasil® (HPV) vaccines.• Co-authored several patents and publications on novel biopharmaceutical process purification steps and analytical assays